IMNN READ THE FULL IMNN RESEARCH REPORT Business Update Phase 3 Ovarian Cancer Trial to Initiate in March 2025 Imunon, Inc. (NASDAQ:IMNN) is continuing preparations to conduct a Phase 3 clinical trial ...

HYDERABAD: India is ready to step in as an alternative site for early-stage clinical trials to help mitigate the impact of ...

Phase 3 topline data from azetukalner FOS epilepsy program planned for H2 2025 in support of NDA filing and potential commercial launch– First ...

NIH funding changes threaten Pittsburgh's biomedical research, risking jobs, innovation and future medical breakthroughs, ...

Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) publishes its year-end report for the period January - December 2024. The report is available on ...

Xenon Pharmaceuticals XENE reported a loss of 84 cents per share for the fourth quarter of 2024, narrower than the Zacks Consensus Estimate of a loss of 89 cents. The company had incurred a loss of 64 ...

Learn more about whether Alnylam Pharmaceuticals, Inc. or argenx SE is a better investment based on AAII's A+ Investor grades ...

We recently published a list of 10 Worst Performing Mid Cap Stocks to Buy According to Analysts. In this article, we are ...

As Rare Disease Day is commemorated on 28 February, experts discuss the barriers to gene therapy access for some rare ...

A global elderly and aging population has significant impacts, not only in terms of individual health risk but in terms of ...

Presentation Date / Time: Saturday, March 8, 2025; 1 p.m. PST ...